首页 > 抗体蛋白 > 抗体
FITC anti-human CD279 (PD-1) Antibody
产品名称:
FITC anti-human CD279 (PD-1) Antibody
产品类别:
抗体
产品编号:
329903
产品应用:
329903
[价格]
规格 价格 库存
25tests ¥ 1272 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3,?immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  15. Radtke AJ,?et al. 2020.?Proc Natl Acad Sci USA. 117:33455-33465. (SB)?PubMed
  16. Radtke AJ,?et al. 2022.?Nat Protoc. 17:378-401. (SB)?PubMed
Product Citations
  1. Fan XL, et al. 2018. Stem Cell Res Ther. 0.493055556. PubMed
  2. Sukegawa K, et al. 2020. Eur J Immunol. 50:1580. PubMed
  3. Shitaoka K, et al. 2018. Cancer Immunol Res. 6:378. PubMed
  4. Yamaguchi S, et al. 2021. Eur J Immunol. 51:2306. PubMed
  5. Zhu W, et al. 2021. Onco Targets Ther. 14:2149. PubMed
  6. Ding L, et al. 2021. Cancers (Basel). 13:. PubMed
  7. Ishizaka A, et al. 2016. J Virol. 90: 5665 - 5676. PubMed
  8. Hess NJ, et al. 2020. J Immunol. 205:272. PubMed
  9. Rueda C, et al. 2015. Hum Immunol. 76:65. PubMed
  10. Jiang N, et al. 2017. Lab Invest. 97:1364. PubMed
  11. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  12. Fujigaki J, et al. 2015. PLoS One. 10: 0132521. PubMed
  13. Fan Z, et al. 2020. EMBO Mol Med. 12:e11571. PubMed
  14. Mao R, et al. 2020. Cancer Sci. 111:3174. PubMed
  15. Yan Y, et al. 2018. JCI Insight. 3. PubMed
  16. Zhang J, et al. 2020. Nat Microbiol. . PubMed
  17. Liu Y, et al. 2017. Oncogene. 10.1038/onc.2017.209. PubMed
  18. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  19. Ho JY, et al. 2021. Mol Ther Methods Clin Dev. 21:237. PubMed
  20. Saraiva DP, et al. 2018. Front Immunol. 2.184027778. PubMed
  21. Jones R, et al. 2009. J Virol. 83:8722. PubMed
  22. Jin C, et al. 2016. EMBO Mol Med. 8: 702 - 711. PubMed
  23. Ramaseri Sunder S, et al. 2020. J Interferon Cytokine Res. 40:310. PubMed
  24. Su Y, et al. 2020. Cell. 1479:183. PubMed
  25. Gao R, et al. 2018. Oncoimmunology. 7:e1438108. PubMed
  26. Loo Yau H, et al. 2021. Molecular Cell. 81(7):1469-1483.e8. PubMed
  27. Pierini S, et al. 2020. JCI Insight. 5:00. PubMed
  28. Nakamoto N, et al. 2009. PLoS One. 5:e1000313. PubMed
  29. Agelidis A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.041. PubMed
RRID
AB_940477 (BioLegend Cat. No. 329903) AB_940479 (BioLegend Cat. No. 329904)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线